enGen (previously Thryve Digital Health) appoints Manoj Kapoor as CEO in India

IMT News Desk
IMT News Desk
· 2 min read

Kapoor brings deep expertise and proven track record of scaling organisations, shaping product portfolios, and fostering innovation

enGen (previously Thryve Digital Health), which has a dedicated GCC for a leading US health insurance plan and hospital network, has appointed healthcare technology veteran Manoj Kapoor as its new Chief Executive Officer. In this role, Kapoor will lead enGen’s operations in India and drive its expansion as a center of excellence for value delivery, innovation, and client success.

Kapoor’s appointment reflects enGen’s commitment to building a robust leadership team that can drive its next phase of growth. With three decades of experience across healthcare technology, venture investment, and business transformation, Kapoor brings deep expertise and proven track record of scaling organisations, shaping product portfolios, and fostering innovation.

Most recently, Kapoor served as Vice President, Growth & Transformation at Providence India, where he spearheaded efforts to transform business operations, uplift efficiency, and enhance patient and caregiver experiences. He has also held senior leadership positions at Optum, including leading the Optum Startup Studio India and heading product engineering, product management, Research & innovation at Optum Global Solutions. Earlier in his career, Manoj worked with RoundGlass Partners, Edifecs, CGI, Dell Services, and Perot Systems, playing instrumental roles across technology-led transformation and business growth initiatives.

Kapoor said, “The opportunity to join enGen and contribute to the mission ‘to create remarkable health experience, freeing people to be their best’ is both inspiring and compelling. I look forward to working closely with our exceptional teams to accelerate innovation, expand our delivery footprint, and create greater value and impact for the enterprise.”

Shrinivas Ayyagari, enGen’s CHRO in India said, “We are delighted to welcome Manoj as our new CEO. His deep expertise in healthcare technology and his proven ability in scaling businesses and leading transformation make him the ideal leader for enGen’s next chapter. With his leadership and guidance, we are confident of strengthening our impact for clients, partners, and the global healthcare ecosystem.”

Kapoor holds an MBA in Finance from the Faculty of Management Studies and an MSc in Operations Research from Delhi University.

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk